Compare Supplements

Side-by-side comparison of 1 supplements

Sgl8.5

Semaglutide

Limited safety

Evidence

Evidence Score8.5/10

Studies: 11

Meta-analyses: 2

Dosage & timing

Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Best Time:

Any time

Can take on empty stomach

Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

Safety

Limited safety

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist

Drug Interactions:

Insulin and sulfonylureas
Oral medications (general)
Other GLP-1 receptor agonists

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Want to compare more supplements?

Loading comparison...